Understanding how prostate cancer drugs interact with a specific part of the androgen receptor
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
This study is looking at how certain prostate cancer treatments connect with a specific part of a protein that helps the cancer grow, which could help scientists create better drugs for men dealing with castration-resistant prostate cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project ID | NIH-10850819 on NIH RePORTER |
What this research studies
This research investigates the binding mechanisms of therapeutics for castration-resistant prostate cancer to the N-terminal domain of the androgen receptor, which is intrinsically disordered. By using advanced computational simulations and experimental techniques like NMR spectroscopy, the study aims to uncover how these drugs interact at a molecular level. This knowledge could lead to the design of more effective treatments for prostate cancer by targeting these disordered regions that are typically challenging for drug development.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with castration-resistant prostate cancer who are seeking new treatment options.
Not a fit: Patients with early-stage prostate cancer or those who are not resistant to standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective therapies for patients with castration-resistant prostate cancer.
How similar studies have performed: Other research has shown promise in targeting intrinsically disordered proteins, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Hanover, United States
- Dartmouth College — Hanover, United States (Active)
Researchers
- Principal investigator: Robustelli, Paul — Dartmouth College
- Study coordinator: Robustelli, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.